HVTN 705 Vaccine Trial Ends—Join Sept 9 webinar to discuss next steps for field

August 31, 2021

Today Johnson & Johnson and partners announced that the Imbokodo study, a large-scale HIV vaccine proof-of-concept trial also known as HVTN 705/HPX2008, did not significantly reduce the overall risk of HIV acquisition among over 2,600 women in five sub-Saharan African countries. The Adenovirus26-based mosaic vaccine regimen was shown to be safe, but it did not meet pre-defined criteria for efficacy to warrant moving forward for longer follow-up. A companion study, the Phase III Mosaico trial, will continue.

Read AVAC’s full statement about the results and what needs to happen next.

Register for a global webinar, scheduled for September 9 at 10am ET to discuss this development and the implications for the HIV vaccine field.

We hope you will bring your questions and your passion. HIV continues to be a global threat. The field can and must learn from these trials and from the success of the COVID-19 vaccine enterprise, to explore new HIV vaccine strategies and bring a lasting end to the epidemic.